Our rapid liquid chromatography-mass spectrometry (rLC-MS) technology innovation and high throughput approaches have removed bioanalytical constraints to map dynamic, non-genetic biomarkers at speed, scale, and in a time- and cost-effective manner.
With more metabolite, lipid, and protein measures made in every sample, you can go beyond the genome to identify novel biomarkers that can inform and accelerate your studies for:
From discovery to preclinical and clinical phases, across disease areas and drug modalities.
From early disease detection to understanding the mechanisms underlying disease risk and progression.